Compile Data Set for Download or QSAR
maximum 50k data
Found 49 Enz. Inhib. hit(s) with all data for entry = 2527
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370063((E)-isopropyl 6-(3,4-difluorobenzoyl)-4,4-dimethyl...)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370111(US10233187, Example 49)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370065((E)-ethyl 6-(3,4-difluorobenzoyl)-3-(4-fluoropheny...)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370066((E)-ethyl 6-(3,4-difluorobenzoyl)-4,4-dimethyl-1,4...)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370067(US10233187, Example 5)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370068(US10233187, Example 6)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370069(US10233187, Example 7)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370070(US10233187, Example 8)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370071(US10233187, Example 9)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370072(US10233187, Example 10)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370073(US10233187, Example 11)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370074(US10233187, Example 12)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370075(US10233187, Example 13)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370076(US10233187, Example 14)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370077(US10233187, Example 15 | US10233187, Example 16)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370077(US10233187, Example 15 | US10233187, Example 16)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370079(US10233187, Example 17)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370080(US10233187, Example 18)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370081(US10233187, Example 19)
Affinity DataEC50:  5.50E+3nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370082(US10233187, Example 20)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370083(US10233187, Example 21)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370084(US10233187, Example 22)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370085(US10233187, Example 23)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370063((E)-isopropyl 6-(3,4-difluorobenzoyl)-4,4-dimethyl...)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370087(US10233187, Example 25)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370088(US10233187, Example 26)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370089(US10233187, Example 27)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370090(US10233187, Example 28)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370091(US10233187, Example 29)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370092(US10233187, Example 30)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370093(US10233187, Example 31)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370094(US10233187, Example 32)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370095(US10233187, Example 33)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370096(US10233187, Example 34)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370097(US10233187, Example 35)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370098(US10233187, Example 36)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370099(US10233187, Example 37)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370100(US10233187, Example 38)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370101(US10233187, Example 39)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370102(US10233187, Example 40)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370103(US10233187, Example 41)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370104(US10233187, Example 42)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370105(US10233187, Example 43)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370106(US10233187, Example 44)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370107(US10233187, Example 45)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370108(US10233187, Example 46)
Affinity DataEC50:  600nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370109(US10233187, Example 47)
Affinity DataEC50:  5.50E+3nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370110(US10233187, Example 48)
Affinity DataEC50:  5.50E+3nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBile acid receptor(Homo sapiens (Human))
Akarna Therapeutics

US Patent
LigandPNGBDBM370064((E)-ethyl 6-(3,4-difluorobenzoyl)-3,4,4-trimethyl-...)
Affinity DataEC50: <200nMAssay Description:Starting from 3.33 mM of compound in DMSO solution, a 10-point 3-fold serial dilution was made by diluting 5 μL of compound into 10 μL of D...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent